Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Surgical technique
- PMID: 15743852
- DOI: 10.2106/JBJS.D.02662
Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. Surgical technique
Abstract
Background: Aseptic nontraumatic osteonecrosis of the femoral head is a disorder that can lead to femoral head collapse and the need for total hip replacement. Since osteonecrosis may be a disease of mesenchymal cells or bone cells, the possibility has been raised that bone marrow containing osteogenic precursors implanted into a necrotic lesion of the femoral head may be of benefit in the treatment of this condition. For this reason, we studied the implantation of autologous bone-marrow mononuclear cells in a necrotic lesion of the femoral head to determine the effect on the clinical symptoms and the stage and volume of osteonecrosis.
Methods: We studied thirteen patients (eighteen hips) with stage-I or II osteonecrosis of the femoral head, according to the system of the Association Research Circulation Osseous. The hips were allocated to a program of either core decompression (the control group) or core decompression and implantation of autologous bone-marrow mononuclear cells (the bone-marrow-graft group). Both patients and assessors were blind with respect to treatment-group assignment. The primary outcomes studied were safety, clinical symptoms, and disease progression.
Results: After twenty-four months, there was a significant reduction in pain (p = 0.021) and in joint symptoms measured with the Lequesne index (p = 0.001) and the WOMAC index (p = 0.013) within the bone-marrow-graft group. At twenty-four months, five of the eight hips in the control group had deteriorated to stage III, whereas only one of the ten hips in the bone-marrow-graft group had progressed to this stage. Survival analysis showed a significant difference in the time to collapse between the two groups (p = 0.016). Implantation of bone-marrow mononuclear cells was associated with only minor side effects.
Conclusions: Implantation of autologous bone-marrow mononuclear cells appears to be a safe and effective treatment for early stages of osteonecrosis of the femoral head. Although the findings of this study are promising, their interpretation is limited because of the small number of patients and the short duration of follow-up. Further study is needed to confirm the results.
Similar articles
-
Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study.J Bone Joint Surg Am. 2004 Jun;86(6):1153-60. doi: 10.2106/00004623-200406000-00006. J Bone Joint Surg Am. 2004. PMID: 15173287
-
Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study.Bone. 2011 Nov;49(5):1005-9. doi: 10.1016/j.bone.2011.07.032. Epub 2011 Jul 29. Bone. 2011. PMID: 21821156
-
Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells.Bone. 2012 Jan;50(1):325-30. doi: 10.1016/j.bone.2011.11.002. Epub 2011 Nov 7. Bone. 2012. PMID: 22094904 Clinical Trial.
-
Core decompression combined with autologous bone marrow stem cells versus core decompression alone for patients with osteonecrosis of the femoral head: A meta-analysis.Int J Surg. 2019 Sep;69:23-31. doi: 10.1016/j.ijsu.2019.06.016. Epub 2019 Jul 10. Int J Surg. 2019. PMID: 31301432 Review.
-
Stem cell therapy for osteonecrosis of the femoral head.Expert Opin Biol Ther. 2005 Apr;5(4):437-42. doi: 10.1517/14712598.5.4.437. Expert Opin Biol Ther. 2005. PMID: 15934823 Review.
Cited by
-
Core decompression combined with bone marrow mononuclear cells in the treatment of femoral head necrosis: a systematic review and meta-analysis.Int J Surg. 2024 Jul 11;110(10):6763-70. doi: 10.1097/JS9.0000000000001625. Online ahead of print. Int J Surg. 2024. PMID: 38990283 Free PMC article.
-
β-catenin inhibition disrupts the homeostasis of osteogenic/adipogenic differentiation leading to the development of glucocorticoid-induced osteonecrosis of the femoral head.Elife. 2024 Feb 20;12:RP92469. doi: 10.7554/eLife.92469. Elife. 2024. PMID: 38376133 Free PMC article.
-
Therapeutic perspectives of exosomes in glucocorticoid-induced osteoarthrosis.Front Surg. 2022 Aug 2;9:836367. doi: 10.3389/fsurg.2022.836367. eCollection 2022. Front Surg. 2022. PMID: 36034358 Free PMC article. Review.
-
Operative Management of Avascular Necrosis of the Femoral Head in Skeletally Immature Patients: A Systematic Review.Life (Basel). 2022 Jan 26;12(2):179. doi: 10.3390/life12020179. Life (Basel). 2022. PMID: 35207467 Free PMC article. Review.
-
Cell therapy for osteonecrosis of femoral head and joint preservation.J Clin Orthop Trauma. 2021 Nov 27;24:101713. doi: 10.1016/j.jcot.2021.101713. eCollection 2022 Jan. J Clin Orthop Trauma. 2021. PMID: 34926146 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
